The persistent reservoir of cells latently infected with human immunodeficiency virus (HIV)-integrated proviral DNA necessitates lifelong suppressive antiretroviral therapy (ART). Epigenetic targeted compounds have shown promise as potential latency-reversing agents; however, these drugs have undesirable toxicity and lack specificity for HIV. We utilized a novel HEK293-derived FlpIn dual-reporter cell line, which quantifies specific HIV provirus reactivation (LTR promoter) relative to nonspecific host cell gene expression (CMV promoter), to identify the 5-substituted 2-acylaminothiazole hit class. Here, we describe the optimization of the hit class, defining the functionality necessary for HIV gene activation and for improving in vitro metabolism and solubility. The optimized compounds displayed enhanced HIV gene expression in HEK293 and Jurkat 10.6 latency cellular models and increased unspliced HIV RNA in resting CD4+ T cells isolated from HIV-infected individuals on ART, demonstrating the potential of the 2-acylaminothiazole class as latency-reversing agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.9b00462 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tannic acid reactivates HIV-1 latency by mediating CBX4 degradation.
J Virol
December 2024
Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.
Article Synopsis
- HIV-1 can integrate into host chromosomes, creating a latent reservoir that makes curing the infection difficult; activating this latency is crucial for eradication.
- Tannic acid (TA) has been identified as a potential latency-reversing agent, effectively reactivating multiple proviruses and showing synergy with other agents.
- TA works by degrading a protein called CBX4, which reduces a specific histone modification (H3K27me3) and enhances the transcriptional activity of HIV-1, suggesting a new strategy for targeting HIV-1 latency.
CBP/p300 lysine acetyltransferases inhibit HIV-1 expression in latently infected T cells.
iScience
December 2024
Department of Biochemistry and Molecular Biology, Molecular Epigenetics Group, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada.
HIV-1 latency is regulated by chromatin modifying enzymes, and histone deacetylase inhibitors (HDACi) cause reactivation of provirus expression. Surprisingly, we observed that inhibitors of the CBP/p300 acetyltransferases also cause reversal of latency in T cells. CBP/p300 inhibitors synergize with various latency reversing agents to cause HIV-1 reactivation.
View Article and Find Full Text PDFMedicinal Plant and Traditional Knowledge-guided Strategies to Combat HIV Persistence.
Curr HIV/AIDS Rep
November 2024
The Wistar Institute, Philadelphia, PA, USA.
Purpose Of Review: Combination antiretroviral therapy (cART) does not act on latent HIV reservoirs, and no latency-reversing agent (LRA) to date consistently reduces viral reservoirs in humans. In Sub-Saharan Africa and elsewhere, complementary and alternative medicines (CAM) are traditionally used to manage HIV/AIDS, including a subset with LRA properties.
Recent Findings: Several plants from the Euphorbiaceae and Thymelaeaceae families have been recently documented for traditional HIV/AIDS management and contain LRAs that function through protein kinase C activation.
NSC95397 Is a Novel HIV-1 Latency-Reversing Agent.
Viruses
November 2024
Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
The latent viral reservoir represents one of the major barriers to curing HIV-1. Focus on the "kick and kill" (also called "shock and kill") approach, in which virus expression is reactivated, and then cells producing virus are selectively depleted, has led to the discovery of many latency-reversing agents (LRAs) that have furthered our understanding of the mechanisms driving HIV-1 latency and latency reversal. Thus far, individual compounds have yet to be robust enough to work as a therapy, highlighting the importance of identifying new compounds that target novel pathways and synergize with known LRAs.
View Article and Find Full Text PDFPierre & Hutch (Euphorbiaceae) Extracts and Isolated Compounds Reverse HIV-1 Latency.
J Exp Pharmacol
November 2024
Center for Drug Discovery, Faculty of Science, University of Buea, Buea, Cameroon.
Background: Pierre & Hutch is a tropical tree that grows in West and Central Africa, used in ethnomedicine to treat cancer, diabetes, headaches, convulsions, urinary diseases, and inflammatory diseases. As other species have been observed to possess chemical compounds that target HIV latency-reversal, we hypothesized that this species may have similar properties.
Aim Of The Study: The identification of extracts and compounds of this species, which have HIV-1 latency-reversing activity in J-Lat T cell lines.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!